Will be interesting to see if any generics manufacturers try to make it after the patent expires. Seems uniquely inimitable.This is the more exciting news for antipsychotics: http://www.in-pharmatechnologist.com/Regulatory-Safety/NDA-for-first-tablet-with-stomach-activated-digital-sensor
This could be a benefit for some patients and definitely would have it's place in treatment planning, but we already have too much focus on medication compliance and control IMO. What I mean by that is that the more we try to make patients do things the more we increase their natural resistance. It's difficult enough to convince a psychotic patient that consistent administration of their medications is in their best interest and the best way to do that is when they trust us. Many of the patients with psychotic disorders that I have spoken with about medications have legitimate concerns about the efficacy and safety of the medications. The more we address those concerns, the better the compliance.This is the more exciting news for antipsychotics: http://www.in-pharmatechnologist.com/Regulatory-Safety/NDA-for-first-tablet-with-stomach-activated-digital-sensor
For this particular drug, I'm more interested in seeing if it might be more effective than Abilify with a similar tolerability profile... but all of the studies I found from a quick PubMed search only compared it to placebo, so I probably won't start prescribing it until/unless I see a study comparing it to another antipsychotic.Doubt we're going to get anything that works better than olanzapine from this approach.